Table 4.
Stratified analysis of odds ratios (95% Confidence intervals) for MetS and its components according to serum Gly levels (per 1-SD increment)
| <65y | P | ≥65y | P | |
|---|---|---|---|---|
| Per SD increment | Per SD increment | |||
| MetS | ||||
| Model 1 a | 0.92 (0.60–1.42) | 0.711 | 0.71 (0.55–0.91) | 0.006 |
| Model 2 b | 0.92 (0.60–1.41) | 0.695 | 0.65 (0.50–0.83) | 0.001 |
| Model 3 c | 0.89 (0.54–1.46) | 0.642 | 0.66 (0.51–0.86) | 0.002 |
| Central obesity | ||||
| Model 1 a | 0.77 (0.50–1.18) | 0.236 | 0.79 (0.64–0.98) | 0.028 |
| Model 2 b | 0.74 (0.48–1.15) | 0.183 | 0.67 (0.54–0.85) | 0.001 |
| Model 3 c | 0.69 (0.43–1.12) | 0.130 | 0.67 (0.52–0.86) | 0.002 |
| Hypertriglyceridemia | ||||
| Model 1 a | 1.14 (0.71–1.83) | 0.586 | 0.77 (0.59–0.99) | 0.046 |
| Model 2 b | 1.11 (0.69–1.78) | 0.668 | 0.70 (0.53–0.91) | 0.007 |
| Model 3 c | 1.15 (0.70–1.88) | 0.574 | 0.72 (0.55–0.94) | 0.016 |
| Hypo-HDL-cholesterolemia | ||||
| Model 1 a | 1.47 (0.94–2.31) | 0.092 | 0.74 (0.56–0.99) | 0.043 |
| Model 2 b | 1.44 (0.90–2.28) | 0.127 | 0.69 (0.51–0.92) | 0.012 |
| Model 3 c | 1.44 (0.88–2.35) | 0.145 | 0.69 (0.51–0.94) | 0.018 |
| Hypertension | ||||
| Model 1 a | 0.97 (0.62–1.53) | 0.893 | 0.95 (0.75–1.19) | 0.633 |
| Model 2 b | 0.96 (0.60–1.52) | 0.850 | 0.95 (0.75–1.20) | 0.679 |
| Model 3 c | 0.97 (0.60–1.57) | 0.890 | 0.94 (0.74–1.21) | 0.633 |
| Impaired fasting glucose | ||||
| Model 1 a | 0.98 (0.64–1.51) | 0.926 | 0.83 (0.67–1.02) | 0.074 |
| Model 2 b | 0.98 (0.63–1.51) | 0.924 | 0.88 (0.70–1.09) | 0.232 |
| Model 3 c | 0.97 (0.61–1.55) | 0.909 | 0.92 (0.73–1.16) | 0.490 |
aModel 1: Crude risk for MetS
bModel 2: Adjusted for age and gender
cModel 3: Further adjusted for smoking status; alcohol drinking; CRP; and family history of diabetes, hypertension, and CAD